Pancreatic Insufficiency Clinical Trial
Official title:
Pancreatic Insufficiency Secondary to Tobacco Exposure
Pancreatic insufficiency is a condition in which there is a decrease in the production and release of enzymes made in the pancreas, which causes nutrient malabsorption. There are many chronic diseases that can lead to pancreatic insufficiency. In the early stages of this disease, a patient may not experience any symptoms, and the prevalence of pancreatic insufficiency may be underestimated. Smoking has long been recognized as a cause of disease in many organs in the body. Cigarette smoke causes inflammation and damages tissue, including the pancreas. Studies have shown that smoking is an independent risk factor for pancreatic cancer and chronic pancreatitis. It has also been shown that the more a person smokes, the worse his disease will be. Additionally, there are studies that show that smokers have nutritional deficiencies. There are observational and retrospective studies that suggest that pancreatic insufficiency may also be caused by smoking. However, this has not been established, and the relationship has not been examined in a controlled manner. This study examines the relationship between smoking and pancreatic insufficiency in patients who do not have other pancreatic diseases.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03279653 -
Pancreatic Exocrine Insufficiency After Bariatric Surgery
|
N/A | |
| Completed |
NCT00763412 -
Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis
|
N/A | |
| Recruiting |
NCT01851694 -
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
|
N/A | |
| Completed |
NCT01710644 -
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01012908 -
Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency
|
Phase 2/Phase 3 | |
| Completed |
NCT01879228 -
Effect of Chronic Incretin-based Therapy in Cystic Fibrosis
|
N/A | |
| Completed |
NCT00705978 -
Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis
|
Phase 3 | |
| Completed |
NCT00095732 -
Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency
|
Phase 2 | |
| Completed |
NCT00513682 -
Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)
|
Phase 3 | |
| Recruiting |
NCT05466838 -
PERT to Improve Quality of Life in Patients Undergoing Pancreaticoduodenectomy: A Pilot Randomized Controlled Trial
|
N/A | |
| Completed |
NCT02979340 -
MRI to Characterize and Predict CF Liver Disease in PUSH Cohort
|
||
| Completed |
NCT00406536 -
Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI
|
Phase 2 | |
| Completed |
NCT00432861 -
Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis
|
Phase 3 | |
| Completed |
NCT01144507 -
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
|
||
| Completed |
NCT05700604 -
Hypoglycemia and Glucagon Response in CF
|
||
| Terminated |
NCT02985801 -
PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03551691 -
Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)
|
Phase 2 | |
| Recruiting |
NCT03450772 -
Equivalence Study to Compare Two Strengths of Creon in China
|
Phase 3 | |
| Completed |
NCT00572975 -
Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea
|
Phase 4 | |
| Completed |
NCT00880100 -
Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)
|
Phase 3 |